Podstawowe statystyki
| CIK | 1808158 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Repare Therapeutics Inc.
SEC Filings (Chronological Order)
Na tej stronie znajduje się pełna, chronologiczna lista zgłoszeń SEC, z wyłączeniem zgłoszeń własności, które udostępniamy gdzie indziej.
| February 19, 2026 |
15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. 001-39335 Commission File Number Repare Therapuetics Inc. (Exact name of registrant as speci |
|
| January 28, 2026 |
As filed with the Securities and Exchange Commission on January 28, 2026 S-8 POS As filed with the Securities and Exchange Commission on January 28, 2026 Registration No. |
|
| January 28, 2026 |
As filed with the Securities and Exchange Commission on January 28, 2026 S-8 POS As filed with the Securities and Exchange Commission on January 28, 2026 Registration No. |
|
| January 28, 2026 |
As filed with the Securities and Exchange Commission on January 28, 2026 S-8 POS As filed with the Securities and Exchange Commission on January 28, 2026 Registration No. |
|
| January 28, 2026 |
As filed with the Securities and Exchange Commission on January 28, 2026 S-8 POS As filed with the Securities and Exchange Commission on January 28, 2026 Registration No. |
|
| January 28, 2026 |
Repare Announces Completion of Acquisition by XenoTherapeutics, Inc. EX-99.1 Exhibit 99.1 Repare Announces Completion of Acquisition by XenoTherapeutics, Inc. CAMBRIDGE, Mass. & MONTREAL (BUSINESS WIRE) – January 28, 2026 – Repare Therapeutics Inc. (“Repare” or the “Company”) announced today the completion of the previously announced acquisition of all of the issued and outstanding common shares of the Company (the “Common Shares” and the holders of the Common Shar |
|
| January 28, 2026 |
As filed with the Securities and Exchange Commission on January 28, 2026 POS AM As filed with the Securities and Exchange Commission on January 28, 2026 Registration No. |
|
| January 28, 2026 |
As filed with the Securities and Exchange Commission on January 28, 2026 S-8 POS As filed with the Securities and Exchange Commission on January 28, 2026 Registration No. |
|
| January 28, 2026 |
As filed with the Securities and Exchange Commission on January 28, 2026 S-8 POS As filed with the Securities and Exchange Commission on January 28, 2026 Registration No. |
|
| January 28, 2026 |
As filed with the Securities and Exchange Commission on January 28, 2026 S-8 POS As filed with the Securities and Exchange Commission on January 28, 2026 Registration No. |
|
| January 28, 2026 |
As filed with the Securities and Exchange Commission on January 28, 2026 S-8 POS As filed with the Securities and Exchange Commission on January 28, 2026 Registration No. |
|
| January 28, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2026 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commis |
|
| January 16, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2026 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commis |
|
| January 16, 2026 |
Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc. EX-99.1 Exhibit 99.1 Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc. CAMBRIDGE, Mass. & MONTREAL (BUSINESS WIRE) – January 16, 2026 – Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced that its Shareholders (as defined below) have approved the acquisition of all of the issued and outstanding common sha |
|
| December 29, 2025 |
Repare Therapeutics Announces Acquisition of Pol EX-99.1 Exhibit 99.1 Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration December 24, 2025 CAMBRIDGE, Mass. & MONTREAL—(BUSINESS WIRE)-Dec. 24, 2025— Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced a definitive asset purchase agr |
|
| December 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2025 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commi |
|
| December 29, 2025 |
EX-2.1 Exhibit 2.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE REPARE THERAPEUTICS INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO REPARE THERAPEUTICS INC. IF PUBLICLY DISCLOSED. ASSET PURCHASE AGREEMENT by and between GILEAD SCIENCES, INC. and REPARE THERAPEUTICS INC. Dated as of Dec |
|
| December 29, 2025 |
EX-10.1 Exhibit 10.1 CONSENT TO ASSIGNMENT Reference is hereby made to that certain Amended and Restated License Agreement (the “Agreement”) made as of July 9th, 2018 by and between New York University (“NYU”) and Repare Therapeutics Inc. (“Repare”). WHEREAS, Section 19 of the Agreement requires Repare to obtain the consent of NYU prior to any assignment of the Agreement. WHEREAS, Repare hereby pr |
|
| December 29, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, fo |
|
| December 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2025 Repare Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Quebec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commi |
|
| December 19, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, fo |
|
| December 15, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, fo |
|
| December 15, 2025 |
DEFM14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 3, 2025 |
PREM14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 3, 2025 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) Repare Therapeutics Inc. |
|
| November 20, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, fo |
|
| November 17, 2025 |
FORM OF D&O VOTING AND SUPPORT AGREEMENT EX-10.1 Exhibit 10.1 FORM OF D&O VOTING AND SUPPORT AGREEMENT November 14, 2025 XENO ACQUISITION CORP. 2200 Powell Street, Suite 310 Emeryville, California 94608 Dear Sirs/Madams: Re: Voting and Support Agreement The undersigned understands that Xeno Acquisition Corp. (the “Purchaser”), XenoTherapeutics, Inc., Repare Therapeutics Inc. (the “Company”) and, solely for purposes of Section 9.15 thereo |
|
| November 17, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2025 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation |
|
| November 17, 2025 |
EX-2.1 Exhibit 2.1 EXECUTION VERSION [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) customarily and actually treated by the registrant as private or confidential. ARRANGEMENT AGREEMENT between XENOTHERAPEUTICS, INC. – and – XENO ACQUISITION CORP. – and – REPARE THERAPEUTICS INC. – and – solely for purposes of Section 9.15, |
|
| November 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2025 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2025 Repare Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Quebec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 14, 2025 |
Exhibit 10.1 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) customarily and actually treated by the registrant as private or confidential. LICENSE AGREEMENT This License Agreement is made and entered into as of July 14, 2025 (the “Execution Date”) and made retroactively effective as of July 1st, 2025 (the “Effective Date |
|
| November 14, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2025 Repare Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Quebec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation |
|
| November 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39335 Repare Therapeutics Inc. |
|
| November 14, 2025 |
EX-99.1 Exhibit 99.1 Repare Therapeutics Enters into Definitive Agreement to be Acquired by XenoTherapeutics, Inc. - Each shareholder is estimated to receive US$1.82 per share plus one CVR per common share - - Transaction expected to close in the first quarter of 2026 - - Additional portfolio monetization efforts continue - - Company reports 3Q 2025 financial results - - $112.6 million in cash and |
|
| October 22, 2025 |
FORM 8-K Item 7.01 Regulation FD Disclosure. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2025 Repare Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Quebec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 8, 2025 |
Exhibit 99.1 Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results Entered into worldwide licensing agreement with Debiopharm for lunresertib Evaluating strategic alternatives to maximize shareholder value Initial data for LIONS and POLAR trials expected to be reported in Q4 2025 $109.5 million in cash and cash equivalents and marketable securities CAMBRIDG |
|
| August 8, 2025 |
Employment Agreement between the registrant and Sandra Alves, dated May 28, 2025. Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into as of the date hereof, by and between Sandra Alves (the “Executive”) and Repare Therapeutics Inc. (the “Company” or “Repare”). WHEREAS, the Company and the Executive wish to enter into this Agreement to set forth the terms and conditions of the Executive’s continued employment with the Company effective M |
|
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 08, 2025 Repare Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Quebec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 8, 2025 |
Exhibit 10.2 EXECUTION COPY CONFIDENTIAL [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) customarily and actually treated by the registrant as private or confidential. SIXTH AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT This Sixth Amendment to Collaboration and License Agreement (this “Sixth Amendment”) is entered into a |
|
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39335 Repare Therapeutics Inc. |
|
| July 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2025 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commissio |
|
| July 16, 2025 |
Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib Exhibit 99.1 Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib July 15, 2025 CAMBRIDGE, Mass. & MONTREAL—(BUSINESS WIRE)-Jul. 15, 2025— Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced it has entered into an exclusive worldwide licensing agreement with Debiopharm Intern |
|
| June 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2025 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commissio |
|
| June 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commissio |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Jurisdiction of Inco |
|
| May 13, 2025 |
Exhibit 10.3 TRANSITION AND SEPARATION AGREEMENT This Transition and Separation Agreement (the “Agreement”) is made by and between Maria Koehler (“Employee” or “you”) and Repare Therapeutics USA Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). RECITALS WHEREAS, Employee has been employed by the Company as its Executive Vice President and Ch |
|
| May 13, 2025 |
Separation and Release Agreement between the registrant and Lloyd M. Segal dated March 31, 2025. Exhibit 10.2 SEPARATION AND RELEASE AGREEMENT BETWEEN: REPARE THERAPEUTICS INC.; (the “Company”) AND: LLOYD M. SEGAL; (the “Executive”) WHEREAS the Executive has served as the Chief Executive Officer of the Company since September 2016; WHEREAS the parties are currently engaged in an employment relationship pursuant to an employment agreement executed on June 12, 2020 (the “Employment Agreement”); |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 Repare Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Quebec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 13, 2025 |
Amendment to Employment Agreement for Steve Forte as of March 31, 2025. Exhibit 10.1 Amendment to the EMPLOYMENT AGREEMENT This Amendment to the Employment Agreement (the "Amendment") is entered into as of March 31, 2025 (the “Effective Date of the Amendment”), by and between Steve Forte (the "Executive") and Repare Therapeutics Inc. (the "Company"). Whereas the Company and the Executive entered into an employment agreement dated June 12, 2020 (the "Employment Agreeme |
|
| May 13, 2025 |
Exhibit 99.1 Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial Results Exploring strategic alternatives to advance clinical stage pipeline and maximize shareholder value $124.2 million in cash and cash equivalents and marketable securities provides runway as of March 31, 2025 CAMBRIDGE, Mass. & MONTREAL (BUSINESS WIRE)—May 13, 2025 — Repare Therapeu |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39335 Repare Therapeutics Inc. |
|
| May 1, 2025 |
Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics Exhibit 99.1 Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics CAMBRIDGE, Mass. & MONTREAL (BUSINESS WIRE)—May 1, 2025— Repare Therapeutics Inc. (“Repare”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that it has out-licensed its discovery platforms, including certain platform and program intellectual property, to |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2025 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39335 Repare Therapeu |
|
| April 29, 2025 |
Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 29, 2025 |
DEFA14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 Repare Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Quebec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 31, 2025 |
Exhibit 99.1 Repare Therapeutics Announces Leadership Transitions Steve Forte, Executive Vice President and Chief Financial Officer, appointed as President, Chief Executive Officer and Director Lloyd M. Segal has resigned as President, Chief Executive Officer and Director to pursue other opportunities CAMBRIDGE, Mass. & MONTREAL (BUSINESS WIRE)—March 31, 2025— Repare Therapeutics Inc. (“Repare” or |
|
| March 3, 2025 |
As filed with the Securities and Exchange Commission on March 3, 2025 As filed with the Securities and Exchange Commission on March 3, 2025 Registration No. |
|
| March 3, 2025 |
Repare Therapeutics Inc. Insider Trading Policy Exhibit 19.1 REPARE THERAPEUTICS INC. INSIDER TRADING POLICY Introduction During the course of your relationship with Repare Therapeutics Inc. (the “Company”), you may receive material information that is not yet publicly available ( “material nonpublic information”) about the Company or about other publicly traded companies with which the Company has business relationships with. Material nonpubli |
|
| March 3, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 03, 2025 Repare Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Quebec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 3, 2025 |
Exhibit 99.1 Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results Initial clinical readout from Phase 1 RP-3467 (Polq ATPase/helicase inhibitor) POLAR trial expected in Q3 2025 Initial clinical readout from Phase 1 RP-1664 (PLK4 inhibitor) LIONS trial expected in Q4 2025 Company reducing its workforce by approximately 75% $152.8 |
|
| March 3, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 Repare Therapeutics Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common shares, no par value per share, 2020 Equity Incentive Plan Other(2) 2,125,535(4) $1 |
|
| March 3, 2025 |
Warrant to Purchase Common Shares issued to Astr Partners LLC, dated November 7, 2024. Exhibit 4.2 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED. REPARE THERAPEU |
|
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39335 Repare Therapeu |
|
| February 25, 2025 |
Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2025 Repare Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Quebec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commi |
|
| January 31, 2025 |
Joint Filing Statement I, the undersigned, hereby express my agreement that the attached Schedule 13D (and any amendments thereto) relating to the beneficial ownership by the undersigned of the equity securities of Repare Therapeutics Inc. |
|
| January 15, 2025 |
Joint Filing Statement I, the undersigned, hereby express my agreement that the attached Schedule 13D (and any amendments thereto) relating to the beneficial ownership by the undersigned of the equity securities of Repare Therapeutics Inc. |
|
| January 10, 2025 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2025 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commiss |
|
| January 10, 2025 |
Exhibit 99.1 Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions Realigning resources to extend runway to mid-2027 Focus on clinical development of RP-1664 (PLK4 inhibitor) and RP-3467 (Polq ATPase inhibitor), with initial clinical readouts expected beginning in Q3 2025 Exploring partnerships for continued development of Lunre+Camo and other assets |
|
| January 6, 2025 |
Joint Filing Statement I, the undersigned, hereby express my agreement that the attached Schedule 13D (and any amendments thereto) relating to the beneficial ownership by the undersigned of the equity securities of Repare Therapeutics Inc. |
|
| December 26, 2024 |
Schedule I General Partners/Members Schedule I General Partners/Members Ansbert Gadicke c/o BioImpact 399 Boylston Street, Suite 1100 Boston, MA 02116 Principal Occupation: Managing director of MPM BioVentures 2014 LLC and managing partner of MPM BioImpact LLC. |
|
| December 26, 2024 |
Joint Filing Statement I, the undersigned, hereby express my agreement that the attached Schedule 13D (and any amendments thereto) relating to the beneficial ownership by the undersigned of the equity securities of Repare Therapeutics Inc. |
|
| December 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2024 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commi |
|
| December 12, 2024 |
EX-99.1 Exhibit 99.1 Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial Heavily-pretreated patients on lunresertib and camonsertib combination achieved 25.9% overall response rate (ORR) in endometrial cancer and 37.5% in platinum-resistant ovarian cancer Nearly half of patients with gynecologic |
|
| December 12, 2024 |
MYTHIC Lunre+Camo Clinical Data Update December 12, 2024 Exhibit 99.2 MYTHIC Lunre+Camo Clinical Data Update December 12, 2024 Safe Harbor Statement Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “anticipates,” “believes,” “expects,” “intends,” “plans,” “potential,” “projects,” |
|
| November 14, 2024 |
RPTX / Repare Therapeutics Inc. / Deep Track Capital, LP Passive Investment SC 13G/A 1 deeptrack-rptx093024a4.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Repare Therapeutics Inc. (Name of Issuer) Common shares, no par value (Title of Class of Securities) 760273102 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appro |
|
| November 14, 2024 |
EX-99.1 2 tm2427858d9ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Shares, no par |
|
| November 14, 2024 |
RPTX / Repare Therapeutics Inc. / Blue Owl Capital Holdings LP - SC 13G/A Passive Investment SC 13G/A 1 ef20038682sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Repare Therapeutics Inc. (Name of Issuer) Common shares, no par value (Title of Class of Securities) 760273102 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the Ap |
|
| November 14, 2024 |
RPTX / Repare Therapeutics Inc. / Redmile Group, LLC - SC 13G/A Passive Investment SC 13G/A 1 tm2427858d9sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4) Repare therapeutics Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 760273102 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the ap |
|
| November 7, 2024 |
Exhibit 99.1 Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results On track to report data from the ongoing MYTHIC dose expansion clinical trial at the recommended Phase 2 dose (RP2D) at a company event in December 2024, with the plan to begin a registrational trial in 2025 Presented updated positive safety and tolerability results from the Phas |
|
| November 7, 2024 |
Up to $100,000,000 Common Shares Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-281298 PROSPECTUS SUPPLEMENT (to Prospectus dated August 19, 2024) Up to $100,000,000 Common Shares We have entered into a sales agreement, or the sales agreement, with TD Securities (USA) LLC, or TD Cowen, relating to our common shares, no par value per share, offered by this prospectus supplement and the accompanying prospec |
|
| November 7, 2024 |
Exhibit 10.1 FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE (this “First Amendment”) dated as of August 26, 2024 (the “Effective Date”), between RREEF AMERICA REIT II CORP. PPP, a Maryland corporation (“Landlord”), and REPARE THERAPEUTICS USA, INC., a Delaware corporation (“Tenant”), related to certain premises located in the building in Riverfront Office Park, Cambridge, Massachusetts at |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39335 Repare Therapeutics Inc. |
|
| November 7, 2024 |
Exhibit 10.2 Repare therapeutics inc. Common Shares SALES AGREEMENT November 7, 2024 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: Repare Therapeutics Inc., a corporation continued under the Business Corporations Act (Québec) (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows: 1. Issuance and |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2024 Repare Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Quebec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 28, 2024 |
Exhibit 99.1 Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio Focuses Company’s resources on its deep clinical oncology pipeline Positioned to advance four clinical programs through multiple upcoming milestones CAMBRIDGE, Mass. & MONTREAL—(BUSINESS WIRE)—Aug. 28, 2024—Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinica |
|
| August 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 15, 2024 |
REPARE THERAPEUTICS INC. 7171 Frederick-Banting, Building 2 Suite 270 St-Laurent, Québec H4S 1Z9 REPARE THERAPEUTICS INC. 7171 Frederick-Banting, Building 2 Suite 270 St-Laurent, Québec H4S 1Z9 Canada August 15, 2024 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Repare Therapeutics Inc. Registration Statement on Form S-3 File No. 333-281298 Ladies and Gentlemen: In accordance with Rule 461 under the Securities A |
|
| August 8, 2024 |
August 8, 2024 Steve Forte Chief Financial Officer Repare Therapeutics Inc. 7171 Frederick-Banting, Building 2, Suite 270 St-Laurent, Qu bec, Canada H4S 1Z9 Re: Repare Therapeutics Inc. Registration Statement on Form S-3 Filed August 6, 2024 File No. 333-281298 Dear Steve Forte: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 4 |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 6, 2024 |
Exhibit 99.1 Repare Therapeutics Provides Business and Clinical Update and Reports Second Quarter 2024 Financial Results Reiterated guidance on data readout from MYTHIC trial evaluating lunresertib and camonsertib in patients with platinum-resistant ovarian and endometrial cancers in Q4 2024 Granted Fast Track designation by the FDA for lunresertib in combination with camonsertib in platinum-resis |
|
| August 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 06, 2024 Repare Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Quebec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 6, 2024 |
Form of Indenture between the Registrant and one or more trustees to be named. Exhibit 4.5 REPARE THERAPEUTICS INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8 Se |
|
| August 6, 2024 |
Form of Preferred Share Warrant Agreement and Warrant Certificate. Exhibit 4.8 REPARE THERAPEUTICS INC. AND , AS WARRANT AGENT FORM OF PREFERRED SHARE WARRANT AGREEMENT DATED AS OF REPARE THERAPEUTICS INC. FORM OF PREFERRED SHARE WARRANT AGREEMENT THIS PREFERRED SHARE WARRANT AGREEMENT (this “Agreement”), dated as of [•], between REPARE THERAPEUTICS INC., a corporation existing under the laws of the province of Québec (the “Company”), and [•], a [corporation] [na |
|
| August 6, 2024 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. Exhibit 4.9 REPARE THERAPEUTICS INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF REPARE THERAPEUTICS INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between REPARE THERAPEUTICS INC., a corporation organized under the laws of the province of Québec (the “Company”), and [•], a [corporation] [n |
|
| August 6, 2024 |
Form of Common Share Warrant Agreement and Warrant Certificate. Exhibit 4.7 REPARE THERAPEUTICS INC. AND , AS WARRANT AGENT FORM OF COMMON SHARE WARRANT AGREEMENT DATED AS OF REPARE THERAPEUTICS INC. FORM OF COMMON SHARE WARRANT AGREEMENT THIS COMMON SHARE WARRANT AGREEMENT (this “Agreement”), dated as of [•], between REPARE THERAPEUTICS INC., a corporation existing under the laws of the province of Québec (the “Company”), and [•], a [corporation] [national ba |
|
| August 6, 2024 |
Power of Attorney (included on signature page). Table of Contents As filed with the Securities and Exchange Commission on August 6, 2024 Registration No. |
|
| August 6, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Repare Therapeutics Inc. |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39335 Repare Therapeutics Inc. |
|
| June 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2024 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 24, 2024 |
Repare Therapeutics Inc. 2024 Inducement Plan Exhibit 99.1 REPARE THERAPEUTICS INC. 2024 INDUCEMENT PLAN ADOPTED BY THE BOARD OF DIRECTORS: APRIL 25, 2024 1. GENERAL. (a) Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3), if applicable, and the related guidance under Nasdaq IM 56 |
|
| May 24, 2024 |
Exhibit 99.2 US Standard Form REPARE THERAPEUTICS INC. 2024 INDUCEMENT PLAN STOCK OPTION GRANT NOTICE Repare Therapeutics Inc. (the “Company”), pursuant to its 2024 Inducement Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of the Company’s Common Shares set forth below. This option is granted in compliance with Nasdaq Listing Rule 5635(c)(4) as a material inducem |
|
| May 24, 2024 |
As filed with the Securities and Exchange Commission on May 24, 2024 As filed with the Securities and Exchange Commission on May 24, 2024 Registration No. |
|
| May 24, 2024 |
Exhibit 99.3 US Standard Form REPARE THERAPEUTICS INC. 2024 INDUCEMENT PLAN RESTRICTED SHARE UNIT GRANT NOTICE Repare Therapeutics Inc. (the “Company”), pursuant to its 2024 Inducement Plan (the “Plan”), hereby awards to Participant a Restricted Share Unit Award for the number of shares of the Company’s Common Shares (“Restricted Share Units”) set forth below (the “Award”). The Award is subject to |
|
| May 24, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 Repare Therapeutics Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common shares, no par value per share Other 350,000(2) $3.17(3) $1,109,500 0. |
|
| May 7, 2024 |
Exhibit 10.1 [***] Certain schedules and exhibits to this exhibit have been omitted pursuant to Item 601(a)(5) of Regulation SK. A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request. FIFTH AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT This Fifth Amendment to Collaboration and License Agreement (this “Fifth Amendment”) is entered into as of March 14, 2024 (the |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39335 Repare Therapeutics Inc. |
|
| May 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 07, 2024 Repare Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Quebec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 7, 2024 |
Exhibit 99.1 Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results Phase 1 MYTHIC clinical trial of lunresertib in combination with camonsertib demonstrated a significant reduction in Grade 3 anemia and continued trends of patient response and benefit; FDA agrees with RP2D First patient dosed in Phase 1 MYTHIC clinical trial of lunresertib in co |
|
| May 7, 2024 |
Insight that enriches. Precision that empowers. Corporate Presentation May 2024 Insight that enriches. Precision that empowers. Corporate Presentation May 2024 Disclaimer Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "anticipates," "believes," "expects," "intends," “plans,” “potential,” "projects,” “ |
|
| April 26, 2024 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 26, 2024 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2024 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commissi |
|
| April 26, 2024 |
UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 FORM10-K (MarkOne) ☒ ANNUALREPORTPURSUANTTOSECTION13OR15(d)OFTHESECURITIESEXCHANGEACTOF1934 ForthefiscalyearendedDecember31,2023 OR ☐ TRANSITIONREPORTPURSUANTTOSECTION13OR15(d)OFTHESECURITIESEXCHANGEACTOF 1934FORTHETRANSITIONPERIODFROM TO CommissionFileNumber001-39335 RepareTherapeuticsInc. (ExactnameofRegistrantasspecifiedinitsChar |
|
| April 26, 2024 |
Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors Exhibit 99.1 Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors CAMBRIDGE, MA & MONTREAL, QC (BUSINESS WIRE)—April 26, 2024— Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Steven H. Stein, M.D., to its Board of Directors, effective as of the date of the Company’s |
|
| February 28, 2024 |
Exhibit 99.1 Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results CAMBRIDGE, Mass. & MONTREAL (BUSINESS WIRE)—February 28, 2024— Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the fourth quarter and full year ended December 31, 2023 |
|
| February 28, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 Repare Therapeutics Inc. Table 1 — Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be Paid Equity Common shares, no par value per share, 2020 Equity Incentive Plan Other( |
|
| February 28, 2024 |
As filed with the Securities and Exchange Commission on February 28, 2024 As filed with the Securities and Exchange Commission on February 28, 2024 Registration No. |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 Repare Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Quebec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39335 Repare Therapeu |
|
| February 28, 2024 |
Incentive Compensation Recoupment Policy of Repare Therapeutics Inc. Exhibit 97 Repare Therapeutics Inc. Incentive Compensation Recoupment Policy 1. Introduction The Board of Directors (the “Board”) of Repare Therapeutics Inc., a corporation continued under the Business Corporations Act (Québec) (the “Company”), has determined that it is in the best interests of the Company and its shareholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) |
|
| February 14, 2024 |
RPTX / Repare Therapeutics Inc. / Deep Track Capital, LP Passive Investment SC 13G/A 1 deeptrack-rptx123123a3.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Repare Therapeutics Inc. (Name of Issuer) Common shares, no par value (Title of Class of Securities) 760273102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the approp |
|
| February 14, 2024 |
RPTX / Repare Therapeutics Inc. / Redmile Group, LLC - SC 13G/A Passive Investment SC 13G/A 1 tm245846d10sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) Repare therapeutics Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 760273102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the app |
|
| February 14, 2024 |
EX-99.1 2 tm245846d10ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Shares, no par |
|
| February 14, 2024 |
RPTX / Repare Therapeutics Inc. / Blue Owl Capital Holdings LP - SC 13G Passive Investment SC 13G 1 ef20021764sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Repare Therapeutics Inc. (Name of Issuer) Common shares, no par value (Title of Class of Securities) 760273102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the Appropria |
|
| February 12, 2024 |
Exhibit 99.1 Repare Therapeutics to Regain Global Rights to Camonsertib Repare will regain control of its potential best-in-class oral small molecule ATR inhibitor CAMBRIDGE, Mass. & MONTREAL—(BUSINESS WIRE)—Feb. 12, 2024—Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, announced today that it will regain global development a |
|
| February 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2024 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commis |
|
| January 29, 2024 |
RPTX / Repare Therapeutics Inc. / ARK Investment Management LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| January 25, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2024 Repare Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Quebec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commis |
|
| January 25, 2024 |
Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment Exhibit 99.1 Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment January 25, 2024 Milestone payment triggered by dosing of the first patient in camonsertib-based arm in Roche’s Phase 2 TAPISTRY platform clinical trial Repare is eligible to receive up to $1.2 billion in potential milestones, plus royalties on global net product sales CAMBRIDGE, Mass. & MONTREAL |
|
| January 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commiss |
|
| January 12, 2024 |
Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones Exhibit 99.1 Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones January 8, 2024 CAMBRIDGE, Mass. & MONTREAL—(BUSINESS WIRE)—Jan. 8, 2024—Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today provided a corporate update and highlighted key milestones anticipated in 2024. “We significa |
|
| November 17, 2023 |
SC 13D/A 1 sc13da107422rptx11172023.htm AMENDMENT NO. 1 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)1 Repare Therapeutics Inc. (Name of Issuer) Common Shares, no par value (Title of |
|
| November 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2023 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 15, 2023 |
EX-99.1 Exhibit 99.1 Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Polq Inhibitor RP-1664 demonstrated potent and selective inhibition of PLK4 and synthetic lethality in TRIM37-high tumor cells in preclinical studies RP-3467 demonstrated complete, sustained regressions preclinically in combination with PARP |
|
| November 9, 2023 |
Exhibit 99.1 Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results Presented positive initial data from ongoing Phase 1 MYTHIC clinical trial evaluating lunresertib alone and in combination with camonsertib, including an overall RECIST response rate of 50% in patients with heavily pre-treated gynecological tumors Repare to host conference call and webcast to |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 09, 2023 Repare Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Quebec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39335 Repare Therapeutics Inc. |
|
| November 3, 2023 |
EX-99.1 2 ex991to13d07422rptx11032023.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D dated November 3, 2023 (including amendments thereto) with respect to the Common Shares, no par |
|
| November 3, 2023 |
RPTX / Repare Therapeutics Inc / BIOTECHNOLOGY VALUE FUND L P - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. )1 Repare Therapeutics Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 760273102 (CUSIP Number) JAMES KRATKY BVF PARTNERS |
|
| October 13, 2023 |
Insight that enriches. Precision that empowers. Corporate Presentation October 2023 Exhibit 99.2 Disclaimer Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "anticipates," "believes," "expects," "intends," “plans,” “potentia |
|
| October 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2023 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commis |
|
| October 13, 2023 |
Insight that enriches. Precision that empowers. Lunresertib MYTHIC Clinical Trial Update October 13, 2023 Exhibit 99.1 Agenda Welcome & Introduction Lloyd M. Segal, President & CEO Lunresertib Preliminary MYTHIC Monotherapy & Combination Therapy Clinical Trial Results Timothy Yap, MBBS, PhD, FRCP, Principal Investigator, MYTHIC Trial Conclusions & Lunresertib Development Plan Maria Koehler, MD, Ph |
|
| October 13, 2023 |
Exhibit 99.1 Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial Evaluating Lunresertib Alone and in Combination with Camonsertib Lunresertib + camonsertib combination demonstrated clear signals of anti-tumor activity across multiple tumor types and all selected genotypes Overall response of 33.3% across all tumor types and 50% RECIST response in patients with he |
|
| October 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2023 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commis |
|
| October 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2023 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 9, 2023 |
Exhibit 99.1 Repare Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results Presented initial camonsertib-PARPi combination Phase 1/2 clinical data at AACR 2023 demonstrating durable clinical benefit across tumor types, genomic alterations, PARPi choice or platinum resistance Roche has included a camonsertib-based arm in its Phase 2 TAPISTRY study and its Phase 1/2 |
|
| August 9, 2023 |
Form of Amendment to Executive Employment Agreement Exhibit 10.2 Amendment to Employment Agreement This Amendment to the Employment Agreement (the “Amendment”) is entered into as of July 13, 2023 (the “Effective Date”), by and between [](the “Executive”) and [Repare Therapeutics Inc.] [Repare Therapeutics USA Inc.] (the “Company”). Recitals A. Effective [],the Company and the Executive entered into an employment agreement (the “Employment Agreement |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39335 Repare Therapeutics Inc. |
|
| August 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 09, 2023 Repare Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Quebec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 9, 2023 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE REPARE THERAPEUTICS INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO REPARE THERAPEUTICS INC. IF PUBLICLY DISCLOSED. FOURTH AMENDMENTTO COLLABORATION AND LICENSEAGREEMENT This Fourth Amendment to Collaboration and License Agreeme |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2023 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2023 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 7, 2023 |
EX-99.1 Exhibit 99.1 Repare Therapeutics Reports Proof of Concept for Lunresertib (RP-6306) in Clinic, Initial Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Insights from Ongoing Combination Trials Findings from the ongoing Phase 1 MYTHIC study demonstrated a favorable and distinctive tolerability profile for monotherapy lunresertib Monotherapy antitumor activity observed, includin |
|
| May 30, 2023 |
Inducement Award Agreement between Repare Therapeutics Inc. and Daniel Belanger, dated May 18, 2023. EX-99.1 Exhibit 99.1 REPARE THERAPEUTICS INC. STOCK OPTION GRANT NOTICE (NONSTATUTORY STOCK OPTION GRANTED OUTSIDE OF THE 2020 EQUITY INCENTIVE PLAN) Repare Therapeutics Inc. (the “Company”) hereby grants to Optionholder an option to purchase the number of the Company’s Common Shares set forth below. This option is granted outside of the Company’s 2020 Equity Incentive Plan (the “Plan”), but shall |
|
| May 30, 2023 |
As filed with the Securities and Exchange Commission on May 30, 2023 S-8 As filed with the Securities and Exchange Commission on May 30, 2023 Registration No. |
|
| May 30, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 Repare Therapeutics Inc. Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be Paid Equity Common shares, no par value per share Other(2) 240,000(3) $9.83 $2,359,20 |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2023 Repare Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Quebec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39335 Repare Therapeutics Inc. |
|
| May 9, 2023 |
EXHIBIT 10.1 [***] Certain schedules and exhibits to this exhibit have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request. LEASE AMENDMENT AGREEMENT No 1 dated effective April 1, 2023 BETWEEN: NEOMED INSTITUTE, duly incorporated under Canada Not-for-profit Corporations Act, having received its certifica |
|
| May 9, 2023 |
Exhibit 99.1 Repare Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results Reported initial camonsertib data from ongoing Phase 1/2 TRESR and Phase 1b/2 ATTACC clinical trials in a plenary oral presentation at 2023 AACR Annual Meeting Camonsertib combination therapy showed 48% CBR across tumor types regardless of choice of PARP inhibitor or platinum resistance, with |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39335 Repare Therapeu |
|
| April 28, 2023 |
DEF 14A Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2023 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commissi |
|
| April 28, 2023 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 28, 2023 |
Repare Therapeutics Appoints Susan Molineaux, Ph.D., to Its Board of Directors EX-99.1 Exhibit 99.1 Repare Therapeutics Appoints Susan Molineaux, Ph.D., to Its Board of Directors CAMBRIDGE, MA & MONTREAL, QC (BUSINESS WIRE)—April 28, 2023— Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Susan Molineaux, Ph.D., to its Board of Directors, effective as of the date of the |
|
| April 18, 2023 |
EX-99.1 Exhibit 99.1 Repare Therapeutics Presents Initial Clinical Data from the Phase 1/2 TRESR and ATTACC Trials Evaluating Camonsertib in Combination with Three PARP Inhibitors at the 2023 AACR Annual Meeting Camonsertib PARPi combinations demonstrated 48% CBR in patients with unmet medical needs, across tumor types, and regardless of PARPi partner or platinum resistance, with a favorable safet |
|
| April 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2023 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 Repare Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Quebec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 1, 2023 |
Power of Attorney (included on the signature page of this Form S-8). S-8 As filed with the Securities and Exchange Commission on March 1, 2023 Registration No. |
|
| March 1, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 Repare Therapeutics Inc. Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be Paid Equity Common shares, no par value per share, 2020 Equity Incentive Plan Other(2 |
|
| February 28, 2023 |
EXHIBIT 10.31 LEASE AMENDING AGREEMENT THIS AGREEMENT is entered into in the city of Montreal (Quebec) as of this October 27th, 2022 (the “Effective Date”). BY AND BETWEEN: NEOMED INSTITUTE, a corporation governed by the Canada Not-for-profit Corporations Act, having its principal place of business at 7171, Frederick-Banting, City of Montreal, Province of Quebec, H4S 1Z9, herein acting and represe |
|
| February 28, 2023 |
EXHIBIT 10.33 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) customarily and actually treated by the registrant as private or confidential. SECOND AMENDMENT TO RESEARCH SERVICES, LICENSE AND COLLABORATION AGREEMENT This Second Amendment to Research Services, License and Collaboration Agreement (this “Second Amendment”) is |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 Repare Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Quebec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 28, 2023 |
Exhibit 99.1 Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results CAMBRIDGE, Mass. & MONTREAL (BUSINESS WIRE)—February 28, 2023— Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the fourth quarter and full year ended December 31, 2022 |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39335 Repare Therapeu |
|
| February 28, 2023 |
EXHIBIT 10.32 AGREEMENT OF LEASE MADE AND ENTERED INTO IN THE CITY OF MONTREAL, PROVINCE OF QUEBEC, THIS 1st DAY OF JANUARY 2023. BY AND BETWEEN: NEOMED INSTITUTE, a corporation governed by the Canada Not-for-profit Corporations Act, having its principal place of business at 7171, Frederick-Banting, City of Montreal, Province of Quebec, H4S 1Z9, herein acting and represented by Matthew Carlyle, CF |
|
| February 14, 2023 |
RPTX / Repare Therapeutics Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 5)1 Repare Therapeutics Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 760273102 (CUSIP Number) December 31, |
|
| February 14, 2023 |
RPTX / Repare Therapeutics Inc / Redmile Group, LLC - SC 13G/A Passive Investment SC 13G/A 1 tm236041d17sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Repare therapeutics Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 760273102 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appr |
|
| February 14, 2023 |
EX-99.1 2 tm236041d17ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, no par v |
|
| February 14, 2023 |
RPTX / Repare Therapeutics Inc / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) REPARE THERAPEUTICS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 760273102 (CUSIP NUMBER) December 31, 2022 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Sched |
|
| February 13, 2023 |
RPTX / Repare Therapeutics Inc / CHI Advisors LLC - CHI ADVISORS LLC Passive Investment SC 13G/A 1 rptxa221323.htm CHI ADVISORS LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Repare Therapeutics Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 760273102 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the a |
|
| February 10, 2023 |
RPTX / Repare Therapeutics Inc / ARK Investment Management LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| February 9, 2023 |
RPTX / Repare Therapeutics Inc / FMR LLC Passive Investment SCHEDULE 13G Amendment No.2 REPARE THERAPEUTICS INC COMMON STOCK Cusip #760273102 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #760273102 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 876,178 Item 6: 0 Item 7: 876,178 Item 8: 0 Item 9: 876,178 Item 11: 2.08 |
|
| January 6, 2023 |
RPTX / Repare Therapeutics Inc / Versant Venture Capital V, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 5)* REPARE THERAPEUTICS INC. (Name of Issuer) Common Shares (Title of Class of Securities) 760273102 (CUSIP Number) Versant Venture Capital V, L.P. Max Eisen |
|
| November 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 09, 2022 Repare Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Quebec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39335 Repare Therapeutics Inc. |
|
| November 9, 2022 |
Exhibit 10.1 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) customarily and actually treated by the registrant as private or confidential. FIRST AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT This First Amendment to Collaboration and License Agreement (this ?Amendment?) amends the Collaboration and License Agreement date |
|
| November 9, 2022 |
Repare Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results Early Phase 1 clinical data readout for RP-6306 is expected in the first half of 2023 Advancing camonsertib development with Roche under worldwide license and collaboration agreement IND-enabling studies for RP-2119, a Pol? inhibitor, currently underway and on track for trial start in summer 2023 Well positioned to advance clinical programs and portfolio, with $370. |
|
| November 9, 2022 |
Exhibit 10.2 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) customarily and actually treated by the registrant as private or confidential. SECOND AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT This Second Amendment to Collaboration and License Agreement (this ?Second Amendment?) amends the Collaboration and License Agree |
|
| August 4, 2022 |
Repare Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results Signed worldwide license and collaboration agreement with Roche for the development and commercialization of camonsertib (also known as RP-3500) Repare received a $125 million upfront payment in July 2022 as part of the collaboration agreement with Roche, and is eligible to receive up to an additional $1. |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 04, 2022 Repare Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Quebec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39335 Repare Therapeutics Inc. |
|
| August 4, 2022 |
Exhibit 10.2 Repare therapeutics inc. Common Shares SALES AGREEMENT August 4, 2022 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Repare Therapeutics Inc., a corporation continued under the Business Corporations Act (Qu?bec) (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1. Issuance and Sale of Sha |
|
| August 4, 2022 |
Exhibit 10.1 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) customarily and actually treated by the registrant as private or confidential. COLLABORATION AND LICENSE AGREEMENT by and between REPARE THERAPEUTICS INC. and HOFFMANN-LA ROCHE INC. and F. HOFFMANN-LA ROCHE LT 272987170 v1 TABLE OF CONTENTS Page Article I Definiti |
|
| August 4, 2022 |
Up to $125,000,000 Common Shares Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-257668 PROSPECTUS SUPPLEMENT (to Prospectus dated April 25, 2022) Up to $125,000,000 Common Shares We have entered into a sales agreement, or the sales agreement, with Cowen and Company, LLC, or Cowen, relating to our common shares, no par value per share, offered by this prospectus supplement and the accompanying prospectus. |
|
| June 13, 2022 |
RPTX / Repare Therapeutics Inc / Versant Venture Capital V, L.P. - SC 13D/A Activist Investment SC 13D/A 1 d325820dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 4)* REPARE THERAPEUTICS INC. (Name of Issuer) Common Shares (Title of Class of Securities) 760273102 (CUSIP Number) Ve |
|
| June 6, 2022 |
SC 13G/A 1 sc13ga407422rptx06062022.htm AMENDMENT NO. 4 TO THE SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 4)1 Repare Therapeutics Inc. (Name of Issuer) Common Shares, no pa |
|
| June 1, 2022 |
Exhibit 99.1 Repare Therapeutics Announces a Worldwide License and Collaboration Agreement with Roche for Camonsertib (RP-3500) Repare will receive a $125 million upfront payment and is eligible to receive up to an additional $1.2 billion in potential development, regulatory, commercial and sales milestones, plus royalties on global net product sales. Repare to host conference call today at 5:00 p |
|
| June 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2022 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Qu?bec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2022 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Qu?bec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 5, 2022 |
Exhibit 99.1 Repare Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results Oral presentation of clinical data from the Phase 1/2 TRESR Trial of camonsertib (also known as RP-3500) monotherapy in solid tumors at 2022 AACR Annual Meeting Results demonstrated robust activity in ovarian cancer with a 75% CBR, 25% ORR and 35 weeks mPFS Results also show 43% CBR in solid |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39335 Repare Therapeutics Inc. |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 05, 2022 Repare Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Quebec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 1, 2022 |
Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 1, 2022 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 11, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 Repare Therapeutics Inc. Table 1 ? Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be Paid Equity Common shares, no par value per share, 2020 Equity Incentive Plan Other ( |
|
| March 11, 2022 |
As filed with the Securities and Exchange Commission on March 11, 2022 As filed with the Securities and Exchange Commission on March 11, 2022 Registration No. |
|
| March 7, 2022 |
As filed with the Securities and Exchange Commission on March 7, 2022 As filed with the Securities and Exchange Commission on March 7, 2022 Registration No. |
|
| March 2, 2022 |
Post-Effective Amendment No. 2 Table of Contents As filed with the Securities and Exchange Commission on March 2, 2022 Registration No. |
|
| March 1, 2022 |
As filed with the Securities and Exchange Commission on March 1, 2022 Table of Contents As filed with the Securities and Exchange Commission on March 1, 2022 Registration No. |
|
| March 1, 2022 |
Employment Agreement between the registrant and Steve Forte, dated June 12, 2020. EXHIBIT 10.11 EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?) is entered into as of June 12, 2020, by and between Steve Forte (the ?Executive?) and Repare Therapeutics Inc. (the ?Company?). WHEREAS, the Company and the Executive wish to enter into this Agreement to set forth the terms and conditions of the Executive?s continued employment with the Company effective and conditional |
|
| March 1, 2022 |
Exhibit 99.1 Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results Cambridge, MA & Montreal, QC, March 1, 2022 (BUSINESS WIRE) - Repare Therapeutics Inc. (?Repare? or the ?Company?) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of nov |
|
| March 1, 2022 |
EXHIBIT 10.27 FIFTH (5TH) AMENDMENT TO LEASE AGREEMENT THIS FIFTH AMENDMENT TO LEASE AGREEMENT made this January-17-2022 BETWEEN: THE MANUFACTURERS LIFE INSURANCE COMPANY (hereinafter called the "Landlord") OF THE FIRST PART, AND REPARE THERAPEUTICS INC. (hereinafter called the "Tenant") OF THE SECOND PART, WHEREAS pursuant to a Lease dated the 15th day of May, 2014 (the "Original Lease") between |
|
| March 1, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 01, 2022 Repare Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Quebec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 1, 2022 |
EXHIBIT 10.28 COMMENCEMENT DATE MEMORANDUM THIS MEMORANDUM, made as of February 25, 2021, by and between RREEF AMERICA REIT II CORP. PPP, a Maryland corporation (?Landlord?) and REPARE THERAPEUTICS USA, INC, a Delaware corporation (?Tenant?). Recitals: (a) Landlord and Tenant are parties to that certain Lease, dated for reference July 13, 2021 (the ?Lease?) for certain premises (the ?Premises?) co |
|
| March 1, 2022 |
EX-FILING FEES 5 d320821dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 Repare Therapeutics Inc. Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be Paid Equity Common shares, n |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K a UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39335 Repare Therap |
|
| February 14, 2022 |
RPTX / Repare Therapeutics Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2022 |
RPTX / Repare Therapeutics Inc / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Repare Therapeutics Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 760273102 (CUSIP NUMBER) December 31, 2021 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Sched |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3)1 Repare Therapeutics Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 760273102 (CUSIP Number) December 31, |
|
| February 14, 2022 |
RPTX / Repare Therapeutics Inc / Redmile Group, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1) Repare therapeutics Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 760273102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| February 14, 2022 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the ?Schedule 13G?) relating to the Common Stock, no par value, of Repare Therapeutics Inc., which may |
|
| February 11, 2022 |
RPTX / Repare Therapeutics Inc / CHI Advisors LLC - CHI ADVISORS LLC Passive Investment SC 13G/A 1 rptxa121122.htm CHI ADVISORS LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Repare Therapeutics Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 760273102 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the a |
|
| February 9, 2022 |
RPTX / Repare Therapeutics Inc / FMR LLC Passive Investment SCHEDULE 13G Amendment No. 1 REPARE THERAPEUTICS INC COMMON STOCK Cusip #760273102 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #760273102 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 42,051 Item 6: 0 Item 7: 3,021,313 Item 8: 0 Item 9: 3,021,313 Item 11: |
|
| February 9, 2022 |
RPTX / Repare Therapeutics Inc / ARK Investment Management LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| January 10, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Qu?bec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commis |
|
| January 7, 2022 |
Repare Therapeutics Provides Corporate Update and Highlights Key Milestones Anticipated in 2022 Exhibit 99.1 Repare Therapeutics Provides Corporate Update and Highlights Key Milestones Anticipated in 2022 Cambridge, MA & Montreal, QC, January 7, 2022 (BUSINESS WIRE) ? Repare Therapeutics Inc. (?Repare? or the ?Company?) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeu |
|
| January 7, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2022 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Qu?bec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 10, 2021 |
Exhibit 99.1 Repare Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results Oral presentation of initial data from the Phase 1/2 TRESR trial at the AACR-NCI-EORTC conference Results demonstrated favorable and differentiated safety profile, along with promising early activity, for RP-3500 in patients with a range of synthetic-lethal genomic alterations Gross Proceeds |
|
| November 10, 2021 |
Exhibit 10.1 FIRST AMENDMENT TO RESEARCH SERVICES, LICENSE AND COLLABORATION AGREEMENT This First Amendment to Research Services, License and Collaboration Agreement (this ?First Amendment?) is entered into as of October 29, 2021 (the ?First Amendment Effective Date?) by and between Repare Therapeutics, Inc., a corporation organized and existing under the laws of Canada and having its principal pl |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 Repare Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Quebec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39335 Repare Therapeutics Inc. |
|
| November 2, 2021 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated November 2, 2021, with respect to the ordinary shares of Repare Therapeutics Inc. |
|
| November 2, 2021 |
LOCK-UP AGREEMENT October 26, 2021 Morgan Stanley & Co. LLC Goldman Sachs & Co. LLC Cowen and Company, LLC Piper Sandler & Co. As Representatives of the several Underwriters listed in Schedule I to the Underwriting Agreement referred to below c/o Morgan Stanley & Co. LLC 1585 Broadway New York, NY 10036 c/o Goldman Sachs & Co. LLC 200 West Street New York, NY 10282-2198 c/o Cowen and Company, LLC |
|
| November 2, 2021 |
RPTX / Repare Therapeutics Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 1 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) Repare Therapeutics Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 760273102 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VII LLC OrbiMed Capital LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-640 |
|
| November 1, 2021 |
Exhibit 1.1 Execution Version 4,000,000 Shares REPARE THERAPEUTICS INC. COMMON SHARES (NO PAR VALUE) UNDERWRITING AGREEMENT October 27, 2021 October 27, 2021 Morgan Stanley & Co. LLC Goldman Sachs & Co. LLC Cowen and Company, LLC Piper Sandler & Co. As Representatives of the several Underwriters named in Schedule I hereto c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o Gold |
|
| November 1, 2021 |
Repare Therapeutics Announces Proposed Public Offering of Common Shares Exhibit 99.1 Repare Therapeutics Announces Proposed Public Offering of Common Shares Cambridge, Mass & Montreal, Quebec, October 27, 2021 ? Repare Therapeutics Inc. (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced the commencement of a proposed underwritten public off |
|
| November 1, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2021 (October 27, 2021) Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Qu?bec 001-39335 Not applicable (State or Other Jurisdiction of Inc |
|
| November 1, 2021 |
Repare Therapeutics Announces Pricing of Upsized Offering of Common Shares Exhibit 99.2 Repare Therapeutics Announces Pricing of Upsized Offering of Common Shares Cambridge, Mass. & Montreal, Quebec, October 27, 2021 ? Repare Therapeutics Inc. (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced the pricing of an upsized underwritten public offe |
|
| October 29, 2021 |
RPTX / Repare Therapeutics Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| October 28, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-257668 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered(1) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Amount of Registration Fee(2) Common shares, no par value 4,600,000 $22.00 $101,200,000 $9,382 (1) Includes 600,000 common shar |
|
| October 27, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-257668 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are part of an effective registration statement filed with the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanyi |
|
| October 8, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2021 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Qu?bec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commiss |
|
| October 8, 2021 |
Exhibit 99.1 Repare Therapeutics Presents Preliminary Phase 1 Monotherapy Clinical Data from the Ongoing First-in-Human Phase 1/2 TRESR Study of RP-3500 in Solid Tumors at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Initial TRESR data provide clinical proof of concept and validate Repare Therapeutics? SNIPRx platform for molecular selection of tumors for th |
|
| September 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2021 (September 6, 2021) Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Qu?bec 001-39335 Not applicable (State or Other Jurisdiction of I |
|
| September 8, 2021 |
Repare Therapeutics Appoints Thomas Civik to its Board and as New Chairman Former CEO of Five Prime Therapeutics brings over 25 years of leadership and commercial experience in pharma, biotech and molecular Dx CAMBRIDGE, Mass. |
